

POSTER PRESENTATIONS AT TIDES USA 2023

PERTH, Australia and SAN FRANCISCO, California – 2 May 2023

PYC today announced upcoming poster presentations highlighting pre-clinical data from its two ocular programs and drug delivery platform at the TIDES USA conference taking place May 7-10, 2023. TIDES is the largest industry event for oligo and peptide therapeutics. PYC staff will present the posters at the conference in-person.

Key Highlights of the poster presentations include:

- The **potency** outperformance of PYC's bi-functional RNA therapeutics over the equivalent 'naked' RNA therapy *in vivo*;
- The **safety and tolerability profile** of PYC's modality for the treatment of retinal diseases in Good Laboratory Practice toxicology studies;
- The **durability** of PYC's modality *in vivo* and how this informs a preferred patient dosing profile in clinical studies; and
- The **disease-modifying potential** of PYC's Retinitis Pigmentosa type 11 (RP11) and Autosomal Dominant Optic Atrophy (ADOA) programs including data:
 - demonstrating modulation of expression of the genes involved in these respective indications; and
 - the restoration of the functional consequences downstream of gene insufficiency, in models derived from patients with RP11 and ADOA after administration of PYC's investigational drug candidates.

The poster presentations can be accessed on demand throughout the meeting by conference attendees on the TIDES USA 2023 website, or on PYC's website in the Posters and Publications section of the [Pipeline](#) page.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorized for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA

info@pyctx.com